Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: SiteTracker	12/24/2004 11:47:36 AM
	of 14101

The key to driving market share growth for Pennsaid? Barneytalks posted the following message on StockHouse in response to another poster's remarks. Thanks Barneytalks! Posted By: barneytalks Post Time: 12/24/04 09:43 Post Number: 8874056 Jim Kayne addressed similar issues in a separate post. Post Number: 8872520 Thanks for posting your views guys! ------------------------------ He doesn't see repeat prescriptions for Pennsaid too often b/c it's not on the provincial formularies.. Getting on the formularies is the key to big growth in Canada... ------------------ I see what you're saying but don't agree the reason for lack of repeats is a lack of formulary approvals -- it's actually the HC approval that is limiting repeats. Formularies would help drive sales growth (no doubt) but wouldn't affect repeats as much as a change to the HC approval. Here's why: Currently the drug is approved for only up to 3 months of consecutive usage in CDA -- this limits sales growth potential significantly due to the fact the company must find another round of users every three months to drive growth. The catalyst for this approval to be changed (for longer term usage) is clearly the long-term studies in progress. With a longer term usage approval provincial formularies will be possible, but not until then. Therefore, long-term studies results are the catalyst that will drive the following: -- better approval in CDA (approval for long-term usage) -- provincial formularies in CDA (due to long-term safety) -- FDA approval (long-term safety) -- a legitimate, safe and proven alternative to COX2s in all markets Therefore, strong results on the long term studies are the key for Pennsaid. Everything else flows from that. Watch the stock on the UP or DOWN following the release of those results and you'll see what I mean. Smart money will flow in if the results show safety for Pennsaid.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next